key: cord-0724219-5ax34rn2 authors: Kute, Vivek; Meshram, Hari Shankar; Sharma, Ashish; Chaudhury, Arpita Ray; Sudhindran, S; Gokhale, AllaGopala Krishna; Hote, Milind; Guleria, Randeep; SinghRana, Devinder; Prakash, Jai; Ramesh, Vasanthi title: Update on COVID-19 vaccine guidelines for transplant recipients date: 2021-10-02 journal: Transplant Proc DOI: 10.1016/j.transproceed.2021.09.007 sha: 79fdd44834552d4a30ec1e6258f407d2621fa159 doc_id: 724219 cord_uid: 5ax34rn2 Coronavirus disease (COVID-19) vaccine and its utility in solid organ transplantation (SOT) needs to be revised timely and updated. These guidelines have been formalized by the experts -the apex technical committee members of the National Organ and Tissue Transplant Organization (NOTTO), and the heads of transplant societies for the guidance of transplant communities. In our general recommendations, we recommend that all personnel involved in organ transplantation should get vaccinated as early as possible and continue COVID-19 appropriate behaviour, despite a full course of vaccination. For specific guidelines of recipients, we suggest completing the full schedule before transplantation whenever the clinical condition permits. We also suggest a single dose, rather than proceeding unvaccinated for transplant, in case a complete course is not feasible. In case, vaccination is planned before surgery, we recommend a gap of at least 2 weeks between the last dose of vaccine and surgery. For those not vaccinated prior to transplant, we suggest waiting for 4-12 weeks after transplant. For the potential living donors, we recommend the complete vaccination schedule before transplant. However, if not feasible, we suggest getting at least a single dose of vaccine, 2 weeks prior to donation. We suggest that suitable transplant patients and those on the waiting list should accept a third dose of the vaccine when one is offered to them. In the context of Vaccine-induced thrombotic thrombocytopenia (VITT), we recommend organs from a deceased donor with suspected/proven VITT should be notified and best avoided and are justified only in case of emergency situations with informed consent and counselling. and Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in children aged 12 and above. The data for safety in pregnancy 10 and children 11 are also promising and it is hoped that these groups will also be included in the near future. The health care communities are at the highest risk of contracting COVID-19 as they are most exposed. They can also be a source of disease spread and nosocomial infection. There is evidence that severity of COVID-19 infection is reduced by vaccination .So, vaccinating them is of paramount importance and highest priority. There are enough studies to document safety and efficacy of COVID-19 vaccines in general. 12, 13, 14, 15 However, there are also reports of breakthrough COVID-19 16 with vaccines. But due to rarity of such instances, and the urgent need of developing an adequate response, immunizing all the staff is highly encouraged. This also calls for continuing practice of COVID-19 appropriate behaviour (wearing face mask, hand hygiene, cough etiquettes, and maintaining social distance). The future will unfold the efficacy of vaccines with different strains and mixing of vaccines, but at current times, vaccinating all health care individuals should be the first stone for restoring fullscale transplantation activities in the COVID-19 era. We recommend 1.1.All personnel involved in organ transplantation to get vaccination as early as possible. after vaccination for tracking vaccination status of candidates on the waiting list and also at time of organ offer and directed inquires by program staff may also be added. Vaccination prior to commencement of immuno-suppression is aimed at improving vaccine efficacy. The data about efficacy of COVID-19 vaccine in waitlisted patients showed a relatively ameliorated response compared to general population, but still a significant proportion of patients develop a robust response ( Table 1) . The chances of acquiring COVID-19 and developing a severe disease in an unvaccinated waitlisted patient are exceedingly higher, compared to a vaccinated one. A majority of waitlisted patients also suffer from co-morbid conditions such as hypertension and diabetes, which makes them highly prone to develop a severe COVID-19 infection. 18 19, 20, 21 The detailed summary of high evidence data regarding vaccination in SOT recipients / waitlisted patients is described in Table 1 .The reported efficacy of vaccines is further reduced in lung and heart recipients compared to liver, the reason being a higher immunosuppression usage with these organs. Hence, checking of antibody response after the doses in these organ recipients could be considered. The protective level of antibody response in SOT is unknown and limits the utility of antibody testing. In general rule, measuring the humoral antibody response or cellular response in all SOT as a guide for dosing is not recommended, and currently should be done in research settings. In general vaccines are safe for SOT as per the current evidence. Other societies have recommended similar intervals between vaccine doses in SOT 22 . 3.1. Completing the entire schedule in SOT preferably prior to transplant or 4-12 weeks after transplant. Covishield which is 12-16 weeks apart, and Covaxin which is 4-6 weeks apart. 3.9. Any available vaccine, and there is no preference of vaccines for SOT. 3.10. All the transplant teams to systematically collect data regarding the vaccine response and adverse events which would prove as a data repository for future studies. 3.11. Further research for dosing, duration, type of vaccine for SOT, as currently available data have proven lower efficacy in SOT than the general population. A preliminary report concluded extending second dose beyond 45 weeks 23 showed higher antibody response and a third dose given at 45 weeks further enhanced the antibody response. The United Kingdom has planned a booster dose-a strategy for vulnerable group to tackle the subsequent waves. 24 A study reported that a booster dose in SOT will develop augmented antibody response. 25 There are on-going RCTs studying the effect of 3rd dose in SOT. 26 A very rare new type of adverse event called Thrombosis with Thrombocytopenia Syndrome (TTS), involving unusual and severe blood clotting events associated with low platelet counts, has been reported after vaccination with COVID-19 Vaccines Vaxzevria and Covishield. A specific case definition for TTS is being developed by the Brighton Collaboration. This will assist in identifying and evaluating reported TTS events and aid in supporting causality assessments. The Global Advisory Committee on Vaccine Safety (GACVS) noted that an investigation has been initiated into the occurrence of Thrombosis with Thrombocytopenia Syndrome (TTS), following the Johnson & Johnson vaccine administered in the United States. Countries assessing the risk of TTS following COVID-19 vaccination should perform a benefit-risk analysis that takes into account local epidemiology (including incidence and mortality from COVID-19 disease), age groups targeted for vaccination and the availability of alternative vaccines. 28 GACVS supports further research to understand age-related risk because while available data suggest an increased risk in younger adults, this requires further analysis. On the issue of sex-related risk, although more cases have been reported in females, it is important to underscore that more women have been vaccinated and that some TTS cases have also been reported in men. Typically, the onset is between 4 to 20 days after adenovirus vectored COVID-19 vaccination. At the minimum, countries should encourage clinicians to measure platelet levels and conduct appropriate radiological imaging studies as part of the investigation of thrombosis event. Clinicians should also be aware that although heparin is used to treat blood clots in general, administration of heparin in TTS may be dangerous, and alternative treatments such as immunoglobulins and non-heparin anticoagulants should be considered. There may be a geographic variation in the risk of these rare adverse events. Vaccine-Induced Thrombotic Thrombocytopenia (VITT) is extremely rare (1.67/100,000) and SOT recipients / waitlisted patients are not a proven risk factor. This association was mostly linked to Oxford/AstraZeneca and Johnson&Johnson's vaccine. 29, 30 There is uncertainly in estimating the high risk individuals in whom VITT can occur. Hemodialysis patients awaiting kidney transplant had frequent history of thrombosis or HIT, but these do not make them prone to increased risk of VITT. At this point, there no evidence that waitlisted or SOT patients are at increased risk for VITT. On suspicion, laboratory investigations -low platelet counts, high D-dimer, low fibrinogen, and high platelet factor 4 (PF-4) antibodies 31 guide towards diagnosis along with CT/MRI findings of thrombosis. No specific treatment is available but intravenous immunoglobulin has shown good results. 32 There is also no evidence for the use of prophylactic anticoagulation to prevent such episode. The risk of VITT is far more in the first dose compared to the second. The second dose, in case of VITT could be continued with a different vaccine, as administering of a different vaccine to the same individual has been safe in preliminary studies. We recommend: On behalf of all the co-authors, as the corresponding author, I declare no competing interest. There is no conflict of interest pertaining to this work. On behalf of all the co-authors, I, as the corresponding author, declare no financial disclosures. This is author's own work and no financial grant or pharmaceutical funding is approved for this work. COVID-19 and Solid Organ Transplantation: A Review Article Clinical Profile and Outcome of COVID-19 in 250 Kidney Transplant Recipients: A Multicenter Cohort Study From India Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network NOTTO COVID-19 vaccine guidelines for transplant recipients NOTTO COVID-19 vaccine guidelines for transplant recipients NOTTO transplant specific guidelines with reference to COVID-19 ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID-19 Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons Covid vaccine could be rolled out to children by autumn Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents Safety and Efficacy of the BNT162b2 mRNA Covid-19 COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid organ transplant recipients Two Doses of SARS-CoV-2 Vaccines Reduce Risk of Death Due to COVID-19 in Solid Organ Transplant Recipients: Preliminary Outcomes From a UK Registry Linkage Analysis Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) Covid-19: Booster dose will be needed in autumn to avoid winter surge, says government adviser. BMJ2021 Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Pathologic Antibodies to Platelet Factor 4 after Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis